Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Epidemiologist Challenges Tamoxifen, Second Cancer Link

January 1, 1997
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 1
Volume 6
Issue 1

An expert panel of 10 international cancer researchers and practicing oncologists met in Boston to discuss the past, present, and future uses of antiestrogens in the treatment of breast cancer.

An expert panel of 10 international cancer researchers and practicingoncologists met in Boston to discuss the past, present, and future usesof antiestrogens in the treatment of breast cancer.

BOSTON--When epidemiologic tools are used to dissect clinical trialresults, potential biases abound, said panel member Robert W. Morgan, MD,an epidemiologist and president of Environmental Health Strategies, MenloPark, Calif.

"Epidemiology is a blunt instrument and delivers rough justice,"he said, so that small increases in risk found by epidemiologic methodsmay not be meaningful, as appears to be the case in the analyses of endometrialcancer risk in patients enrolled in trials of tamoxifen (Nolvadex).

Dr. Morgan described six potential areas of bias in cohort studies that,he said, severely limit our ability to gather conclusions from these studiesabout the risk of second cancers in women taking tamoxifen therapy. Thesame problems can apply to case-control studies, he added. The possiblebiases are:

  • Post hoc design. The original tamoxifen studies were designedto look at efficacy, not at endometrial cancer risk, so that all the necessarydata to analyze a possible relationship were not collected. The studieslooking at a possible relationship of tamoxifen and endometrial cancerwere designed after the fact.
  • Surveillance bias. "Any time you have a group of peopleunder study, they will report an increased rate of almost any disease imaginable,"Dr. Morgan said.
  • Ascertainment bias. This is the likelihood of diagnosing a preexistingdisease through increased medical surveillance. At least two of the cohortstudies have shown that women in the tamoxifen arm have triple the rateof gynecological exams as the control group. "If you're tripling therate of examination, then you are more likely to find the underlying tumorsif they are there," he said.
  • Patient compliance problems. In many of these studies, it wasfound that not all patients in the study group actually received tamoxifenand that some control patients did manage to get the drug.
  • Latency issues. Endometrial cancer can exist in a latent, subclinicalphase for many years, Dr. Morgan said. When endometrial cancers are foundjust a few months after initiation of tamoxifen treatment, "it seemsagainst common sense to attribute these to tamoxifen," he said.
  • Lack of data concerning estrogen replacement therapy (ERT).Although ERT is not generally recommended in breast cancer patients, Dr.Morgan said that it is being prescribed on a fairly regular basis for womenwith breast cancer without regard as to whether they are enrolled in atrial, and "virtually none of these studies have good data on ERT,which, I believe, is a major confounder of the findings."

The effect of each of these biases, he said, is to increase the apparentrelative odds and relative risk of endometrial cancer attributed to tamoxifen.

In his review of 18 studies of endometrial cancer risk in tamoxifentrials, Dr. Morgan found that only two showed any significant increasedrisk for tamoxifen users. "And in both these studies, the magnitudeof the risk depends on how you look at it," he said. For example,in NSABP B-14, the relative risk ranged from as low as 2.1 to as high asinfinity, depending on which set of controls were used as a comparisongroup.

The NSABP researchers used three comparison groups: the nontamoxifencontrol group within the study (which had no endometrial cancers, promptingthe investigators to seek other comparison groups); a control group fromanother study; and a control group based on SEER data on cancer incidence.

The last group gave the lowest relative risk of 2.1. "And in epidemiology,relative risks of 2 are not very high," Dr. Morgan said.

He also pointed out that since breast cancer and endometrial cancershare a common epidemiology, women who have had breast cancer are alreadyat increased risk of endometrial cancer whether or not they take tamoxifen.

Thus, much of the increased risk seen when the incidence of endometrialcancer in tamoxifen users was compared with that of the general populationfrom SEER data could be explained by the common epidemiology.

The other study to show a significant increase in risk (Stockholm, 1993,reported by Fornander) gave a range of relative risk of 3 to 6, dependingon which assumptions the investigators made, "whether you throw outthe people who did not have true cancer, whether you include people whonever received the drug and cross over the controls who did take it,"he said.

Furthermore, in both of these studies, many of the endometrial cancercases were reported within the first 2 years after tamoxifen therapy began."This short latency period makes it implausible that tamoxifen isthe primary cause, although the data are compatible with tamoxifen eitherpromoting an existing tumor or producing changes such as bleeding thatlead to diagnosis," he said.

Dr. Morgan ended with the plea that investigators plan clinical studieswith epidemiologic concerns in mind from the beginning. This would includeclose monitoring of patient compliance, to make sure patients are not crossingover to the other side of the trial, and data on confounders such as useof ERT.

Articles in this issue

New Board to Deal With Cancer Policy Issues
MoAb Shows Positive Results in Lymphoma Patients
Prostate Cancer Gene Location Narrowed to Chromosome 1 Arm
New BCG Bladder Cancer Indication Gets Panel Nod
Panel Advises FDA To OK Letrozole for Advanced Breast Cancer
Limited Diagnostic Testing After Breast Cancer Treatment Urged
Pressures of Managed Care Spur Interest in Clinical Guidelines
Baltimore Will Head New Effort To Develop a Vaccine for HIV
Epidemiologist Challenges Tamoxifen, Second Cancer Link
Cancer Care's AIDS Pain Booklet Available
AIDS Center Director Offers Advice on Selecting a Physician
Good Outcomes Seen With Hyperfractionated Conformal RT
Goals of Planned National Pain Research Consortium Outlined
New Evidence Supports Screening in Younger Women
Interferon Improves Survival in CML

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

Russ Conroy
July 24th 2025
Article

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Roman Fabbricatore
July 18th 2025
Article

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

Anthony Zisa;Marcelo Sleiman Jr;Muriel Statman;Duye Liu;Adina Fleischmann;Kenneth Tercyak
July 16th 2025
Article

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

Caroline Oska;Eleni Kohilakis;Jana Fox
July 15th 2025
Article
Related Content

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

Russ Conroy
July 24th 2025
Article

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Roman Fabbricatore
July 18th 2025
Article

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

Anthony Zisa;Marcelo Sleiman Jr;Muriel Statman;Duye Liu;Adina Fleischmann;Kenneth Tercyak
July 16th 2025
Article

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

Caroline Oska;Eleni Kohilakis;Jana Fox
July 15th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.